| pubmed-article:18390242 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18390242 | lifeskim:mentions | umls-concept:C0444626 | lld:lifeskim |
| pubmed-article:18390242 | lifeskim:mentions | umls-concept:C1516634 | lld:lifeskim |
| pubmed-article:18390242 | lifeskim:mentions | umls-concept:C1261322 | lld:lifeskim |
| pubmed-article:18390242 | lifeskim:mentions | umls-concept:C0011373 | lld:lifeskim |
| pubmed-article:18390242 | lifeskim:mentions | umls-concept:C0023981 | lld:lifeskim |
| pubmed-article:18390242 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:18390242 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:18390242 | pubmed:dateCreated | 2008-4-8 | lld:pubmed |
| pubmed-article:18390242 | pubmed:abstractText | Contemporary plasma-sprayed hydroxylapatite (HA) coatings with high crystalline content are much more resistant to in vivo degradation than HA coatings of a decade ago but reportedly exhibit reduced wettability, which could potentially negatively affect tissue adhesion and long-term clinical outcome. The present prospective study was undertaken to determine if highly crystalline HA MP-1-coated implants could meet a minimum 5-year implant success rate standard of 85% in view of their previously reported decreased wettability. Study subjects were consecutive patients with 1 or more missing teeth in the maxillary and/or mandibular jaw who presented in 3 university dental clinics and 1 private dental practice. A total of 120 patients were treated per protocol and successfully restored with implant-supported prostheses. Four implants failed in 3 patients and were withdrawn from the study. There were no other irresolvable adverse events. Cumulative implant success at 5 years was 97% (n = 184 implants in 88 patients), which exceeded the 85% standard for implant success after 5 years of clinical function. | lld:pubmed |
| pubmed-article:18390242 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18390242 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18390242 | pubmed:citationSubset | D | lld:pubmed |
| pubmed-article:18390242 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18390242 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18390242 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18390242 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18390242 | pubmed:issn | 0160-6972 | lld:pubmed |
| pubmed-article:18390242 | pubmed:author | pubmed-author:TarnowDennis... | lld:pubmed |
| pubmed-article:18390242 | pubmed:author | pubmed-author:RiversJames... | lld:pubmed |
| pubmed-article:18390242 | pubmed:author | pubmed-author:DavliakosJohn... | lld:pubmed |
| pubmed-article:18390242 | pubmed:author | pubmed-author:KeithJ... | lld:pubmed |
| pubmed-article:18390242 | pubmed:author | pubmed-author:SandersJohn... | lld:pubmed |
| pubmed-article:18390242 | pubmed:author | pubmed-author:ThiererToddT | lld:pubmed |
| pubmed-article:18390242 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18390242 | pubmed:volume | 34 | lld:pubmed |
| pubmed-article:18390242 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18390242 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18390242 | pubmed:pagination | 39-46 | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:meshHeading | pubmed-meshheading:18390242... | lld:pubmed |
| pubmed-article:18390242 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18390242 | pubmed:articleTitle | Five-year prospective clinical evaluation of highly crystalline HA MP-1-coated dental implants. | lld:pubmed |
| pubmed-article:18390242 | pubmed:affiliation | University of Rochester Medical Center, Rochester, NY 14642, USA. Todd_Thierer@urmc.rochester.edu | lld:pubmed |
| pubmed-article:18390242 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18390242 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:18390242 | pubmed:publicationType | Evaluation Studies | lld:pubmed |
